Suppr超能文献

急性髓性白血病患者骨髓细胞中的基因重排

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.

作者信息

Schmetzer H M, Braun S, Wiesner D, Duell T, Gerhartz H H, Mittermueller J

机构信息

Klinikum Grosshadern, Medical Department III, University of Munich, Munich, Germany.

出版信息

Acta Haematol. 2000;103(3):125-34. doi: 10.1159/000041035.

Abstract

At diagnosis, clonal gene rearrangement probes [retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3)] were detected in bone marrow samples from 71 of 153 patients with acute myelogenous leukemia (AML) (46%): in 41 patients with primary AML (pAML) (58%) and in 30 patients with secondary AML (42%). In all cases with promyelocytic leukemia (AML-M3) RAR-alpha gene rearrangements were detected (n = 9). Gene rearrangements in the Ig-JH or the TcR-beta or GM-CSF or IL-3 or MLL gene were detected in 12, 10, 16 and 12% of the cases, respectively, whereas only few cases showed gene rearrangements in the M-bcr (6%) or G-CSF gene (3%). Survival of pAML patients with TcR-beta gene rearrangements was longer and survival of pAML patients with IL-3 or GM-CSF gene rearrangement was shorter than in patients without those rearrangements. No worse survival outcome was seen in patients with rearrangements in the MLL, Ig-JH or M-bcr gene. In remission of AML (CR), clonal gene rearrangements were detected in 23 of 48 cases (48%) if samples were taken once in CR, in 23 of 26 cases (88%) if samples were taken twice in CR and in 23 of 23 cases (100%) if samples were studied three times in CR. All cases with gene rearrangements at diagnosis showed the same kind of rearrangement at relapse of the disease (n = 12). Our data show that (1) populations with clonal gene rearrangements can be regularly detected at diagnosis, in CR and at relapse of AML. (2) Certain gene rearrangements that are detectable at diagnosis have a prognostic significance for the patients' outcome. Our results point out the significance of gene rearrangement analyses at diagnosis of AML in order to identify 'poor risk' patients - independently of the karyotype. Moreover, the persistence of clonal cells in the further course of AML can be studied by gene rearrangement analysis.

摘要

在诊断时,153例急性髓系白血病(AML)患者中有71例(46%)的骨髓样本中检测到克隆基因重排探针[维甲酸受体(RAR)-α、主要断裂点簇区域(M-bcr)、免疫球蛋白(Ig)-JH、T细胞受体(TcR)-β、髓系淋巴样白血病(MLL)或细胞因子基因(GM-CSF、G-CSF、IL-3)]:41例原发性AML(pAML)患者(58%)和30例继发性AML患者(42%)。在所有早幼粒细胞白血病(AML-M3)病例中均检测到RAR-α基因重排(n = 9)。Ig-JH、TcR-β、GM-CSF、IL-3或MLL基因重排在病例中的检出率分别为12%、10%、16%和12%,而仅有少数病例显示M-bcr(6%)或G-CSF基因(3%)重排。TcR-β基因重排的pAML患者生存期较长,而IL-3或GM-CSF基因重排的pAML患者生存期短于无这些重排的患者。MLL、Ig-JH或M-bcr基因重排的患者未观察到更差的生存结局。在AML缓解期(CR),若CR期采集一次样本,48例中有23例(48%)检测到克隆基因重排;若CR期采集两次样本,26例中有23例(88%)检测到;若CR期研究三次样本,23例中有23例(100%)检测到。所有诊断时基因重排的病例在疾病复发时均显示相同类型的重排(n = 12)。我们的数据表明:(1)在AML诊断时、CR期和复发时可定期检测到克隆基因重排群体。(2)诊断时可检测到的某些基因重排对患者的预后具有重要意义。我们的结果指出了AML诊断时基因重排分析的重要性,以便识别“高危”患者——独立于核型。此外,可通过基因重排分析研究AML病程中克隆细胞的持续性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验